Partnering Companies
Cevec: Single cell line tech to move protein expression rapidly to market
Cevec Pharmaceuticals uniquely offers a single human cell line from original research all the way to market-scale production with CAP-T, a transient cell line for rapid protein expression in drug discovery and development as a complement to the Cevec amniocyte high yield production (CAP) technology.
Partnering People
Merck Serono Venture Fund: Fresh funding for early stage deals
In what has proven to be a turbulent period for the biotech industry since Merck Serono launched its corporate venture fund in March, one deal has been announced, and Bulthuis hinted he may have news to discuss at BIO-Europe 2009 when he participates in the panel discussion “Funding Early Stage Programs in Difficult Times.” Read more »
Gathering over 1,700 delegates from 1,061 companies in only its fourth year, BIO-Europe Spring 2010 provided proof of principle for conference producer EBD Group that “Partnering is here to stay in life sciences.”
This year offered a compelling demonstration that the introduction of BIO-Europe Spring in 2006 created the right event at the right Read more »
Climbing out of the depressed conditions brought on by the great financial crisis of 2009, dealmaking regained some of its vigor during BIO-Europe Spring® 2010 in Barcelona. Confirming that the spring may indeed be back in biotech dealmaking, privately owned Cellzome and Glaxo used this high profile partnering venue to announce a drug discovery deal Read more »
Hoping to escape the long winter across many parts of Europe and North America, delegates arriving for BIO-Europe Spring 2010 in sunny Spain were greeted by a sudden winter storm that covered Barcelona under a blanket of snow.
Throughout the afternoon as the storm gathered force, delegates snapped photos with cell phones to record the Read more »
If we learn from our failures, then Alzheimer’s disease presents the most exciting therapeutic area for drug discovery as it is a field littered with some of the most spectacular late stage wrecks in pharmacological research.
A complex disease, Alzheimer’s offers a range of targets that is surpassed only by the number of companies, universities, research Read more »
Market opportunities in China are staggering, yet it was a question of trust that dominated the Q&A period following the BIO-Europe Spring® panel discussion “Why China Should be Factored into a Company’s Development and Commercialization Strategy.”
The central point of several members of the audience was to ask, “If I believe China can match quality standards Read more »
Big pharma is searching for niche opportunities to tease out further growth, moving into the rare diseases and regional markets that are the hunting ground for midsize companies.
Leading a panel discussion asking “Can Mid-cap Companies Succeed with Targeted Regional Strategies?” moderator Jeff Conroy with Adjuvant Global Advisors set a context for competition highlighting the February Read more »
Venture capitalists have a well earned reputation for being hard nosed and matter of fact, so it was a rare opportunity to explore the leading edge of investment theory in a workshop session at BIO-Europe Spring® 2010 playfully titled, “The Virtues of Being Virtual.”
Organized by the partners in Competitive Drug Development International, Grahaem Brown and Read more »
Spanish biotechnology is growing nearly 15 percent annually. Montserrat Vendrell says that is three times higher than German growth and five times higher than USA. Although the information is downplayed by countries, Spain is the country that has experienced the best biotechnological results in the last seven years.
Hot Companies
Newsletter